Cowen reissued their buy rating on shares of Surface Oncology (NASDAQ:SURF) in a report released on Thursday morning, AnalystRatings.com reports.
Other analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Surface Oncology from a strong-buy rating to a hold rating in a research report on Wednesday, May 8th. ValuEngine cut shares of Surface Oncology from a buy rating to a hold rating in a research report on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $17.63.
Surface Oncology stock opened at $4.22 on Thursday. The firm has a market cap of $120.52 million and a PE ratio of -12.79. Surface Oncology has a fifty-two week low of $3.45 and a fifty-two week high of $18.18.
Several hedge funds have recently added to or reduced their stakes in the stock. American International Group Inc. grew its holdings in shares of Surface Oncology by 54.3% during the 4th quarter. American International Group Inc. now owns 7,441 shares of the company’s stock valued at $32,000 after purchasing an additional 2,620 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of Surface Oncology by 19.4% during the 1st quarter. California State Teachers Retirement System now owns 17,724 shares of the company’s stock valued at $85,000 after purchasing an additional 2,877 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Surface Oncology by 8.3% during the 4th quarter. Bank of America Corp DE now owns 88,773 shares of the company’s stock valued at $376,000 after purchasing an additional 6,795 shares during the last quarter. Meeder Asset Management Inc. bought a new position in shares of Surface Oncology during the 4th quarter valued at $30,000. Finally, Rhumbline Advisers bought a new position in shares of Surface Oncology during the 1st quarter valued at $54,000. 59.76% of the stock is currently owned by institutional investors.
About Surface Oncology
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27.
Featured Article: What is a recession?
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.